Frontiers in Genetics (Aug 2022)

Recent advances of the mammalian target of rapamycin signaling in mesenchymal stem cells

  • Huarui Cai,
  • Huarui Cai,
  • Zhongze Wang,
  • Zhongze Wang,
  • Wenhan Tang,
  • Xiaoxue Ke,
  • Xiaoxue Ke,
  • Erhu Zhao,
  • Erhu Zhao

DOI
https://doi.org/10.3389/fgene.2022.970699
Journal volume & issue
Vol. 13

Abstract

Read online

Mammalian target of rapamycin (mTOR) is a serine/threonine kinase involved in a variety of cellular functions, such as cell proliferation, metabolism, autophagy, survival and cytoskeletal organization. Furthermore, mTOR is made up of three multisubunit complexes, mTOR complex 1, mTOR complex 2, and putative mTOR complex 3. In recent years, increasing evidence has suggested that mTOR plays important roles in the differentiation and immune responses of mesenchymal stem cells (MSCs). In addition, mTOR is a vital regulator of pivotal cellular and physiological functions, such as cell metabolism, survival and ageing, where it has emerged as a novel therapeutic target for ageing-related diseases. Therefore, the mTOR signaling may develop a large impact on the treatment of ageing-related diseases with MSCs. In this review, we discuss prospects for future research in this field.

Keywords